Intas Pharmaceuticals
Tracked across 5 events · 34 articles · First seen Jun 09, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Domestic
Impact: Intas Pharmaceuticals>>> is a generic drugmaker in India>>> producing platinum-based chemotherapy, facing challenges due to platinum shortages and price caps.
Jun 09, 2026 · 9 articles
Regulatory
Impact: Intas Pharmaceuticals is the parent company of Intas Pharmaceuticals, which lost the patent challenge, delaying its generic Sacubitril/valsartan launch in the UK and potentially affecting its market strategy.
Aug 13, 2026 · 6 articles
Regulatory
Impact: Separately had a Class II recall for subpotent levothyroxine tablets, highlighting broader quality issues in thyroid medications.
Aug 25, 2026 · 6 articles
Business
Biocon, an Indian biopharmaceutical company, signed a partnership agreement with Bahiafarma, a public pharmaceutical laboratory of the State of Bahia, and Bionovis, a Brazilian biotechnology company, to manufacture and commercialize Pertuzumab, a monoclonal antibody for…
Impact: As a competitor in biosimilars, Intas may face increased competition in Brazil's public market.
Sep 08, 2026 · 6 articles
Regulatory
Biopharmaceutical, a wholly-owned subsidiary of Biocon, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Union — European Medicines Agency issued a positive opinion recommending marketing authorisation for its Pertuzumab…
Impact: Indian pharmaceutical company mentioned among domestic marketers of Pertuzumab biosimilar alternatives in India.
Sep 21, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Intas Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard